Abstract
A series of eleven benzyloxyamines has been evaluated for in vitro and in vivo inhibition of dopa decarboxylase. The effect of these inhibitors on the rise in [14C]amines in the brain after [14C]dopa has also been assessed. Of these compounds, 3,4-dihydroxybenzyloxyamine appears to be a potent selective peripheral inhibitor of dopa decarboxylase. Its activity is similar to that of Ro 4–4602 [N1-(dl-seryl)-N2-(2,3,4-trihydroxybenzyl) hydrazine].